Wednesday, May 18, 2011
Micromet Inc., of Bethesda, Md., published Phase II data showing that blinatumomab produced durable remissions in front-line acute lymphoblastic leukemia. While a 22 percent molecular response rate was expected, 80 percent of patients achieved a complete molecular response, all within the first cycle of treatment. Blinatumomab is an anti-CD19 antibody.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.